Spondin-2 is a novel diagnostic biomarker for laryngeal squamous cell carcinoma

Pathol Res Pract. 2019 Feb;215(2):286-291. doi: 10.1016/j.prp.2018.11.017. Epub 2018 Nov 29.

Abstract

Spondin-2, belongs to the SOX (SRY-related HMG box) gene family, plays a vital role in the development of malignancy, however, the role of Spondin-2 in laryngeal squamous cell carcinoma (LSCC) remains unknown. The aim of this study is to investigate the prognostic significance of and probable mechanism of Spondin-2 in LSCC. qRT-PCR, western blotting assays and IHC analysis demonstrated that Spondin-2 was significantly increased in LSCC tissues compared with adjacent non-tumorous tissues. In addition, high levels of Spondin-2 was associated with clinical stage, lymph node metastasis and pathology grade of LSCC patients (P <0.05). Kaplan-Meier analysis showed that patients with high expression of Spondin-2 had a lower overall survival rate (P<0.05) than that with low expression of Spondin-2. Moreover, spondin-2 silencing inhibited the proliferation of LSCC cells through inhibiting the activation of PI3K/AKT signaling. In conclusion, spondin-2 might be a novel therapeutic target and prognostic biomarker for LSCC patients.

Keywords: 5-year survival ratio; Clinicopathological characteristics; LSCC; PI3K/AKT signaling pathway; Prognostic biomarker; Spondin-2.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / analysis*
  • Extracellular Matrix Proteins / analysis*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Laryngeal Neoplasms / diagnosis*
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / pathology
  • Male
  • Middle Aged
  • Neoplasm Proteins / analysis*
  • Prognosis
  • Squamous Cell Carcinoma of Head and Neck / diagnosis*
  • Squamous Cell Carcinoma of Head and Neck / mortality
  • Squamous Cell Carcinoma of Head and Neck / pathology

Substances

  • Biomarkers, Tumor
  • Extracellular Matrix Proteins
  • Neoplasm Proteins
  • SPON2 protein, human